Labiana
Labiana is publishing an informative guide to help its shareholders understand how subscription rights work and the different alternatives available during the capital increase.
Labiana Health has been recognized as a success story on BME Growth by Bolsas y Mercados Españoles (BME), which highlights the company’s evolution since its IPO and its growth as a pharmaceutical group specializing in human and animal health, being the first veterinary pharmaceutical laboratory to be listed on the stock exchange in Spain.
Labiana Health has secured €37 million in syndicated financing and will execute a pre-emptive capital increase. The transaction enhances its credit profile and supports organic and inorganic growth.
Labiana has completed the validation of the analytical methods for cannabis flowers intended for therapeutic use according to the European Pharmacopoeia. This allows the company to certify producers or distributors worldwide that their batches comply with the specifications required by current regulations.
Labiana, the pharmaceutical laboratory specializing in animal and human health and listed on BME Growth, will bring its new line of products for women’s health and wellness to CPHI, the most important annual trade fair in the pharmaceutical sector, taking place from October 28 to 30 in Germany.
Specifically, Labiana — which specializes in the development and manufacturing of both its own products and those for third parties (CDMO) — will present, as part of its human health portfolio, two food supplements and one cosmetic product.
In recent years, medicinal cannabis has attracted significant interest within the medical and scientific communities. The most studied and recognized compounds of this plant are tetrahydrocannabinol (THC) and cannabidiol (CBD), both of which possess important therapeutic properties. However, terpenes—also present in cannabis—have begun to gain relevance in research due to their potential effects on the modulation and synergy with cannabinoids. This article explores the role of terpenes within the context of medicinal cannabis, highlighting their importance in the development of new treatments.
Labiana Health, the Spanish pharmaceutical group specializing in human and animal health, has published a communication through BME Growth, the Spanish alternative stock market where it is listed, disclosing an unaudited preliminary report on its consolidated financial results for the first half of the fiscal year in 2025.
Labiana, the pharmaceutical company specializing in animal and human health listed on BME Growth, is reinforcing its corporate governance with the appointment of Carme Hortalà as a new independent director and Juan Ortiz as a new proprietary director.
Labiana, the pharmaceutical company specializing in both animal and human health and listed on BME Growth, returns this year to the MedCap Forum—the key event for European small and mid-cap investors listed in Spain—to present its business model and expansion plan to interested investors.
Labiana, the pharmaceutical laboratory specializing in both animal and human health and listed on BME Growth, will present its latest additions to its product portfolio at the ANEMBE International Congress of Bovine Medicine, taking place from May 28 to 30 in Vitoria. Among the highlights is a new antibiotic with zero milk withdrawal time in dairy cattle.